Azaadamantane Derivatives for Selective nAChR Modulation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current compounds that interact with nicotinic acetylcholine receptors (nAChRs) lack subtype selectivity, leading to adverse effects such as cardiovascular and gastrointestinal problems, and are addictive, necessitating the development of subtype-selective compounds that mimic the beneficial effects of nicotine while minimizing its adverse consequences.
Innovation Solution
Development of azaadamantane ester and carbamate derivatives that selectively interact with α7 and α4β2 nicotinic acetylcholine receptors, modulating their activity to treat various cognitive disorders and conditions without the adverse effects associated with non-selective nicotine interaction.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If non-selective nicotine compounds are used to interact with nAChRs, then broad physiological effects are achieved, but adverse effects such as cardiovascular and gastrointestinal problems occur
Solution Approach 1:
The patent segments the non-selective nicotine compound into multiple selective ligands, each targeting specific nAChR subtypes (α4β2, α7, α9α10). This segmentation allows the therapeutic effects to be achieved through targeted interaction with specific receptor subtypes rather than broad non-selective binding, thereby reducing adverse effects on cardiovascular and gastrointestinal systems.
Solution Approach 2:
The patent applies local quality by designing ligands with specific molecular structures that confer selectivity for particular nAChR subtypes. Each ligand has tailored chemical properties (such as aromatic rings, basic nitrogens, and specific functional groups) that enable it to interact preferentially with its target receptor subtype, achieving localized therapeutic action rather than systemic effects.
2Adaptability or versatility
If non-selective nicotine compounds are used, then cognitive and physiological effects are achieved, but addiction occurs
Solution Approach 1:
The patent segments the broad-spectrum nicotine activity into targeted subtype-specific ligands. By focusing on specific nAChR subtypes involved in cognitive functions (such as α4β2 and α7 receptors in the brain), the ligands achieve cognitive effects without activating reward pathways associated with addiction, thereby improving reliability.
Solution Approach 2:
The patent uses selective ligands as intermediaries that mediate cognitive effects through specific receptor subtypes without triggering the addictive mechanisms. These ligands act as precise mediators that can modulate neurotransmitter release and neuronal excitability in cognitive circuits without activating the mesolimbic dopamine system responsible for addiction.
3Object-affected harmful factors
If subtype-selective compounds are developed, then adverse effects are reduced, but compound specificity and selectivity must be precisely achieved
Solution Approach 1:
The patent employs parameter changes by systematically modifying molecular parameters of the ligands (such as basic nitrogen pKa, aromatic ring substitution patterns, and functional group positioning) to optimize selectivity for specific nAChR subtypes. These parameter adjustments allow fine-tuning of receptor affinity and selectivity, achieving the desired specificity while managing the complexity of compound development.
Data Source
AI summary
The invention relates to compounds that are substituted azaadamantane ester and carbamate derivatives, compositions comprising such compounds, and methods of using such compounds and compositions.